Combined with our in vitro findings showing exarafenib’s activity against RAS-driven signaling, PDX results suggest that pan-RAF inhibition may offer therapeutic potential for the substantial subset of NSCLC patients harboring concurrent BRAF-RAS mutations, though clinical validation will be essential. This evidence concerns the gene RAF1 and non-small cell lung carcinoma.